Cosciens Biopharma (FRA:ET8) Asset Impairment Charge : €0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Cosciens Biopharma Asset Impairment Charge?

Cosciens Biopharma's Asset Impairment Charge for the three months ended in Mar. 2025 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2025 was €0.00 Mil.

Cosciens Biopharma Asset Impairment Charge Historical Data

The historical data trend for Cosciens Biopharma's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosciens Biopharma Asset Impairment Charge Chart

Cosciens Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Asset Impairment Charge

Get a 7-Day Free Trial

4.07

Cosciens Biopharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Cosciens Biopharma Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Cosciens Biopharma Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Cosciens Biopharma's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosciens Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cosciens Biopharma Inc (FRA:ET8) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

CSCI:USA ET8:Germany CSCI:Canada

Address

c/o Norton Rose Fulbright Canada LLP, 222 Bay Street, Suite 3000, P.O. Box 53, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.

Cosciens Biopharma Headlines

No Headlines